Inspired by **patients.**
Driven by **science.**

Transforming Rheumatology

At UCB we embrace the possibility to **transform the lives** of people with immune-mediated inflammatory diseases and osteoporosis.

- Psoriatic Arthritis
- Axial Spondyloarthritis
- Systemic Lupus Erythematosus
- Osteoporosis

By building on our expertise and our patient-centric mindset, we are committed to establishing a solid foundation of solutions for patients in partnership with the scientific community to elevate care.

Our rheumatology story

- Our solid foundation
- Evolving science
- Meaningful and trusted long-term partnerships
- Harnessing innovative technology and science

Our solid foundation

We have a long-standing commitment to patients with psoriatic arthritis, axial spondyloarthritis, lupus and osteoporosis, underpinned by our dedication to addressing their unmet needs as they evolve.

A footprint in **56** countries

Paving the way for **improved care of women of childbearing age** living with severe chronic diseases

A unique mix of expertise, innovation and ambition to **pioneer and accelerate scientific advancements**

Our commitment to women of childbearing age

Globally, **200 million women** become pregnant each year[1]

85% out of almost 2,000 women across 74 countries reported a need for information about medications during pregnancy or lactation[2]

Stopping treatment for **chronic diseases during pregnancy** in some instances can cause symptoms to worsen and diseases to progress[2]

Uncontrolled disease activity might result in **adverse pregnancy outcomes** and impact neonatal health[3,4]

Evolving science

We are using advanced science to deliver and expand value for people living with immune-mediated inflammatory diseases with unmet needs in rheumatology.

We are exploring **new approaches** to move from symptomatic treatment to disease modification and cure

Our evolving portfolio is looking at ways to serve **new patient populations**, to allow them to achieve a better quality of life

We are investigating new treatment indications that can help patient populations with **very high unmet needs**

We place patients at the heart of everything we do

From discovery → to development → to delivery

We leverage these insights to inform our science and develop innovative and differentiated solutions for people living with rheumatic diseases.

Our innovative portfolio

We focus on driving scientific advancements in chronic immune-mediated inflammatory diseases such as psoriatic arthritis, axial spondyloarthritis and systemic lupus erythematosus, where there is a remaining high **unmet need** and great potential to provide long-term **value for people living with these diseases.**

We are investigating treatments for diseases with **very high unmet need** that aim to bring the highest possible impact with ongoing early clinical development programs

We are exploring innovative solutions through our vibrant preclinical drug development program, including disruptive treatments with immune reset potential which provides **long-term drug-free remission**

We aim to double remission rates, across all these indications, by **2030** through innovative solutions

We have worked to deepen **our understanding of axial spondyloarthritis and psoriatic arthritis** to better support people living with these conditions and **bring them life-changing solutions**

Meaningful and trusted long-term partnerships

We are constantly motivated to support the large number of people affected by immune-mediated inflammatory diseases; a goal made possible through our meaningful and trusted partnerships and ongoing collaborations.

- **Patients**
- **Scientific communities**
- **Organizations with technology and data capabilities**
- **Regulatory bodies**

EuroSpA – Scientific collaboration of 16 European registries that collect data from patients with SpA.

Accelerating Medicines Partnership®: Autoimmune and Immune-Mediated Diseases (AMP®-AIM) – Foundation for the US National Institutes of Health (FNIH) initiative to dissect unique disease-centric pathways for psoriatic spectrum disease and other systemic autoimmune disorders.

FOREUM (Foundation for Research in Rheumatology) – Partnership promotes health in people living with rheumatic and musculoskeletal diseases through effective research.

Harnessing innovative technology and science

We embed cutting-edge technologies and digital innovation into everyday care for patients with immune-mediated inflammatory diseases in rheumatology. We do this to deliver a personalized experience, helping to accelerate early intervention and reduce time to diagnosis.

Our goal is to remove roadblocks on the patient journey and to provide patients with the best experience across that journey.

Incubator DCT

With our incubator program, ‘Digital Care Transformation’, we partner with healthcare’s most talented start-ups to generate pioneering innovations.

BoneBot: Innovative AI technology to increase identification of spinal fractures

- **200 million people** worldwide affected by osteoporosis[5]
- **More than 8.9 million fragility fractures** each year[6]

FASTRAX: Digital health platform designed to improve primary care physician recognition of pain, assessment of axial spondyloarthritis patients and access to rheumatology care

AARDVARK: Advancing Access in Rheumatology: Delivering Value from AI-based workflows

Developed in partnership with Aetion and Quinten Health, AARDVARK leverages real-world data with AI algorithms to better understand people living with psoriatic arthritis and axial spondyloarthritis

Inspired by patients, and driven by science, we are UCB.

To learn more about UCB’s commitment to rheumatology, visit www.ucb.com/disease-areas

References: **1.** Fowler JR, Mahdy H, Jack BW. Pregnancy (2022). **2.** EMA. Workshop on benefit-risk of medicines used during pregnancy and breastfeeding. Last accessed: January 2023. **3.** Fitzpatrick L, et al. J Am Acad Dermatol. 2022;86(1):46–54. **4.** Gottlieb AB, et al. Int J Womens Dermatol. 2019;5(3):141–150. **5.** Reginster JY, Burlet N. Bone. 2006;38(2 Suppl 1):S4–9. **6.** Ström O, Borgström F, Kanis JA, et al. Arch Osteoporos. 2011;6:59–155.

Inspired by **patients.**
Driven by **science.**

GL-N-DA-RH-2200124
Date of preparation: February 2023
© UCB Biopharma SRL, 2023. All rights reserved